Memorial Sloan Kettering’s David M. Rubenstein Center for Pancreatic Cancer Research, established in 2014 with generous support from David M. Rubenstein, aims to improve the lives of patients with pancreatic malignancies through bold, innovative, multidisciplinary research.
This pursuit is urgent, as pancreatic cancer is currently the fourth leading cause of cancer death in the United States and is expected to become the second leading cause by 2020. Members of the Rubenstein Center are working collaboratively to make pancreatic cancer a more manageable and potentially curable disease.
Led by an internationally renowned team of clinicians and scientists, the Rubenstein Center has established the following strategic priorities:
- Recruiting new faculty members whose research will focus entirely on pancreatic cancer
- Providing enhanced education and support for pancreatic cancer patients and their families
- Facilitating daily interactions between scientists and clinicians caring for pancreatic cancer patients
- Expanding Memorial Sloan Kettering’s substantial portfolio of clinical trials for pancreatic cancer patients, including an enhanced effort to move the development of new drugs to phase 1 trials
- Creating enabling infrastructure and resources to augment translational and clinical research on pancreatic cancer and foster collaborations within Memorial Sloan Kettering’s research community and beyond
- Providing grant funding to support creative and innovative pancreatic cancer research, including outstanding projects that might be considered too exploratory or preliminary to be funded by traditional mechanisms
- Training the next generation of pancreatic cancer investigators and clinicians